Literature DB >> 21176951

Rituximab maintenance in follicular lymphoma: PRIMA.

Jonathan W Friedberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21176951     DOI： 10.1016/S0140-6736(10)62272-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

2.  Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).

Authors:  Stefan K Barta; Hailun Li; Howard S Hochster; Fangxin Hong; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Natalia Colocci; Elizabeth M Bengtson; Sandra J Horning; Brad S Kahl
Journal:  Cancer       Date:  2016-06-28       Impact factor: 6.860

Review 3.  Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?

Authors:  Roswitha Forstpointner; Martin Dreyling
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

4.  Intratracheal exposure to Fab fragments of an allergen-specific monoclonal antibody regulates asthmatic responses in mice.

Authors:  Shin Yoshino; Nobuaki Mizutani; Daiko Matsuoka; Chutha Sae-Wong
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.